Nilotinib Stada (Nilotinib)

Nilotinib selectively binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This stops downstream signaling that drives uncontrolled proliferation of leukemic cells, leading to reduced tumor burden and improved clinical outcomes.

The specific dose of Nilotinib Stada is determined by the prescribing physician based on the patient’s disease status, body weight, renal and hepatic function, and other clinical factors. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for nilotinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation as advised by their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor with higher potency against many resistant BCR‑ABL mutations compared with first‑generation agents like imatinib. It offers a distinct safety profile, including a higher risk of QT prolongation, and may be preferred when patients have intolerance or resistance to earlier‑line therapies.

Nilotinib Stada tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in humid environments such as bathrooms, and keep the product out of reach of children.

Nilotinib Stada is taken orally, usually with a low‑fat meal to improve absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients should follow the timing and dietary instructions given by their prescriber.

The most serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatic toxicity, pancreatitis, and significant reductions in blood cell counts that may cause infection or bleeding. Patients should be monitored regularly for these events.

Nilotinib Stada is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, in those with a history of prolonged QT interval, and in individuals taking strong CYP3A4 inhibitors that cannot be discontinued. It should also be used with caution in patients with pre‑existing liver disease or severe electrolyte disturbances.